Alume Biosciences

About

Alume Biosciences is a biotechnology company developing nerve-targeted pharmaceuticals for surgical and therapeutic use.

San Diego,California,United States
1 - 10
https://alumebiosciences.com/

Highlights

Details

Last Funding Type: Grant
Last Funding Money Raised: $3.40M
Industries: Biotechnology,Life Science,Medical
Founded date: Jan 1, 2017
Number Of Employee: 1 - 10
Operating Status: Active
Legal Name: Alume Biosciences, Inc.

Alume is a biotechnology company, developing nerve-targeted pharmaceutical agents for surgical and therapeutic use. The company's first product, ALM-488, is a fluorescently labeled peptide-dye conjugate that makes human nerves "glow," helping surgeons reduce injury to critical nerves during surgery.

During surgery, inadvertent injury to nerves leads to loss of function, including paralysis, numbness, and decreased quality of life. Alume intends to develop agents including ALM-488 to be used as an adjunct during surgery to help surgeons see nerves better compared to current visualization with white light alone. Alume's technology has the potential to improve the accuracy of nerve identification, decrease operative time, and lead to better outcomes for patients.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

3

$14.67M

Alume Biosciences has raised a total of $14.67M in funding over 2 rounds. Their latest funding was raised on Sep 9, 2022 from a Grant round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Sep 9, 2022	Grant	$3.40M	1	National Institute of Neurological Disorders and Stroke	—	Detail
May 1, 2020	Series A	$5.50M	2	—	—	Detail
Jun 28, 2019	Series Unknown	$5.77M	—	—	—	Detail